Toll-like receptor 2 (TLR2) is a marker of angiogenesis in the necrotic area of human medulloblastoma

Folia Neuropathologica
Danuta MaslinskaDariusz Szukiewicz

Abstract

Angiogenesis plays a key role in the progression of malignant tumors. In recent years, anti-angiogenic drugs have been shown to be effective against tumors. However, some tumors are able to adopt escape mechanisms, suggesting that the vascular network in these tumors may be formed or may function in a different way. Medulloblastomas are tumors characterized by poor prognosis and low patient survival rates. These tumors rarely metastasize, but the reason why they almost always recur locally is not known. Central to mediating neoplastic changes is the interaction between cell surface receptors and their cognate ligands, which through intracellular signaling induce alternations in gene expression. In this context, the aim of our present study was to examine in medulloblastoma the distribution of Toll-like receptor 2 (TLR2) and receptor for advanced glycosylation end-product (RAGE), and mast cells associated with the tumor neovascularization process. Immunohistochemical study with a battery of specific antibodies was used. The results show that in the tumor necrotic area, TLR2 participates in all steps of vascular network formation, but in regions where the tumor was not affected by necrosis, the capillary network was TLR2 immunone...Continue Reading

Related Concepts

Related Feeds

Angiogenesis Inhibitors to Treat Cancer

Cancer treatments including angiogenesis inhibitors prevent tumor cells from receiving nutrients and oxygen. Here is the latest research on angiogenesis inhibitors for the treatment of cancer.

Related Papers

Advances in Experimental Medicine and Biology
Eduardo Díaz-Rubio
Cancer Chemotherapy and Pharmacology
Saroj KunnakkatAshwatha Narayana
Journal of Cancer Research and Clinical Oncology
P M Biselli-ChicoteE M Goloni-Bertollo
© 2022 Meta ULC. All rights reserved